Omico

23/02/2026

Precision oncology works. Access is the challenge.

Outside of self-pay or clinical trials, Omico is the only national pathway providing coordinated, access to molecular profiling and treatment matching at no cost to patients.

Continuity of PrOSPeCT protects patient access today — and helps build the path to routine, mainstream care tomorrow.

👉 Read the submissionhttps://omico.org.au/wp-content/uploads/2026/02/Securing-PrOSPeCT-for-the-future_Final.pdf



UNSW UNSW Medicine & Health Cancer Institute NSW Children's Cancer Institute

20/02/2026

Every 15 minutes, an Australian with incurable cancer is referred to Omico for access to precision oncology. Their needs are urgent.

Access to precision oncology is not yet routine or equitable in Australia—and continuity of PrOSPeCT matters for people who can’t wait.

No eligible patient should miss out because access to PrOSPeCT is disrupted.

👉 Read the submissionhttps://omico.org.au/wp-content/uploads/2026/02/Securing-PrOSPeCT-for-the-future_Final.pdf



UNSW UNSW Medicine & Health Cancer Institute NSW Children's Cancer Institute

17/02/2026

Securing PrOSPeCT: continuity today, mainstream care tomorrow.

Every 15 minutes, an Australian with incurable cancer is referred to PrOSPeCT.

Access to precision oncology is not yet routine or equitable in Australia. Continuity of PrOSPeCT ensures uninterrupted access to genomic profiling and treatment matching at no cost to patients — while longer-term arrangements for mainstream care are considered.

Based on current demand, existing funding is projected to be exhausted by September 2026. Omico has submitted its 2026–27 Pre-Budget Submission seeking continuation funding through to the end of 2028.

We encourage you to read the submission and stay informed as this next phase unfolds.

👉 Read the submissionhttps://omico.org.au/wp-content/uploads/2026/02/Securing-PrOSPeCT-for-the-future_Final.pdf



UNSW UNSW Medicine & Health Cancer Institute NSW Children's Cancer Institute

09/02/2026

Recently, our Exec team took time out together—not just to focus on 2026 priorities, but to look further ahead at where we’re heading over the next 10 years.

It was about people. Program participants we continue to follow over time, the new cohorts to begin, and the science that keeps evolving.

It was about translating that science into better outcomes for people facing cancer—and turning innovation and evidence into better care, smarter policy and real-world impact.

Grateful for this team, and energised by what’s ahead.
Real people. Real work.

Pictured (Left to Right): Kym Bramich, Lucille Sebastian, Jessica Oliver, Mandy Ballinger, David Thomas, James Odell, Waman Tamhankar, Ian Black, James Ferderow, Vera Terry, Jenn Henderson, Tanya Slater, Ron Chan

09/02/2026

🎸 We got the band together!

Recently, David Thomas was referred to as a bit of a rockstar. So we started a band: Spot and the Rubicons.

“Crossing the Rubicon” is one of David’s favourite expressions. It represents a bold commitment to change, a point of no return. It felt so aligned with Omico’s purpose that we made band T-shirts. Of course we did!!

To mark on 4 Feb, we surprised the Omico team with band tees and said thanks — for the way they keep pushing what’s possible, grounded in science and driven by evidence.

Accelerating access to precision oncology is serious work. Recognising the people doing it, and the impact that work has on individuals, families and communities, matters just as much 💙

(And in case you were wondering… Spot is a cat, and a regular cameo in our online meetings. 🐾)




📸Picture: some members of the band

06/02/2026

📣 Our first eNewsletter for 2026 is now available—delivered this week coinciding with

This edition shines a spotlight on education, including a final reminder to register for APOS 26, upcoming events, and on-demand access to recent sessions. You’ll also read about the impact for Australians who access our programs, meet Omico’s Molecular Oncology Board, learn about a collaborative project at the Royal Darwin Hospital focused on improving equitable access to genomic profiling for Aboriginal and Torres Strait Islander Peoples, and see new publications and board members.

🔗 Read the February 2026 issue: https://bit.ly/3ZljinB
✉️ Subscribe to receive future editions: https://omico.org.au/webform/

Our next issue will be released in March.

04/02/2026

For people living with rare cancers, connection and trusted information matter.

The Chordoma Foundation’s first Australian Community Day in Sydney on 7 Feb brings patients, families and experts together for a day of support, learning and shared experience, and to hear the about latest on research and treatment.

The speaker lineup includes Omico founder Prof David Thomas, alongside Australian and international experts.

If this is relevant to you or someone you love, see the post below for more info, and to register.




Rare Cancers Australia Cooper Rice-Brading Foundation
UNSW UNSW Medicine & Health Cancer Institute NSW Children's Cancer Institute

It’s not too late to join us at Chordoma Community Day Australia on Sat., Feb 7 in Sydney!

Register: chordoma.org/event/2026-ccd-australia

It's a chance to learn from an incredible lineup of speakers on topics that can affect every stage of the chordoma journey, and to connect with others who truly understand what you’re going through. Knowing you are not alone can make a real difference! We hope to see you there 💙🇦🇺

Misty Bland Omico

04/02/2026

For people with incurable and hard-to-treat cancers, having evidence-based options matters.
Comprehensive genomic profiling looks closely at what’s driving an individual’s cancer and can help identify targeted treatments or clinical trial options that may not otherwise be considered.

At Omico, an Australian with incurable cancer is referred to us, on average, every 15 minutes—supporting access to precision oncology while also building the data and evidence needed to make this approach part of routine cancer care for all who could benefit.

On World Cancer Day, we thank every participant, clinician and family who has helped build this knowledge—not only for today’s patients, but for those who will follow.



👉 Visit our website to learn more: https://www.omico.com.au/



UNSW UNSW Medicine & Health Cancer Institute NSW Children's Cancer Institute Rare Cancers Australia Love Your Sister

30/01/2026

Progress in precision oncology doesn’t only happen in labs or clinics—it’s also shaped by the people helping guide the work behind the scenes.

We’re pleased to welcome Greg Couttas and Professor Alexander Swarbrick to the Omico Board.

Greg brings deep experience in governance, audit and risk, built through senior leadership roles at Deloitte and across public, private and not-for-profit organisations.

Professor Swarbrick brings leading scientific expertise from his work at the Garvan Institute of Medical Research and UNSW Sydney, helping connect research and evidence with real-world clinical care.

Together, the Board continues to guide Omico’s work to support Australians with unmet cancer needs, and to progress precision oncology toward becoming standard of care.

👉 Learn more about Omico’s Board: https://www.omico.com.au/about-us/our-board/

21/01/2026

Professor David Thomas asks:
💬“Can we afford the successes of science?”

Our Impact Report shows that we can — and that it benefits Australians in more ways than one.

Support for Omico (around $300M in funding from government, philanthropy and industry) has helped advance cancer care while also enabling:
🔹$280M+ in additional investment for Australia
🔹1,500+ jobs created nationally in under 3 years

As David said:
💬“It’s possible to deliver cutting-edge precision medicine to patients, support clinicians and boost the Australian economy at the same time.”

📘 Omico’s Impact Report – From Momentum to Mainstream: https://bit.ly/44JG6jY
📊 Omico’s Impact Scorecard: https://bit.ly/4rJKd9u

Australians can’t wait. It’s time to mainstream precision oncology for those who need it most.

15/01/2026

Behind each CaSP report is a team of specialists bringing decades of expertise to one person’s cancer.
Week by week, Australia’s cancer community benefits from the experts who analyse complex molecular profiling results and identify targeted treatment options.

As we continue International across the week, we thank Omico’s Molecular Oncology Board for their extraordinary contribution: more than 15,000 participants have now received matched therapy recommendations — supporting oncologists, guiding decisions, and opening new treatment pathways.

Link: https://www.omico.com.au/our-programs/cancer-screening-program-casp/

Matching

15/01/2026

Precision oncology doesn’t happen in isolation.

It happens because 81 cancer centres across metro and regional Australia choose to collaborate, innovate and push for better options for people with incurable and hard-to-treat cancers — creating more chances for them to access clinical trials of new, precision treatments that may be more effective, or offer additional options when choices are limited.

This week we’re extending International to thank every centre in Omico’s National Clinical Trial Network for the role they play in driving transformation in cancer care across the country.

Link: https://www.omico.com.au/about-us/our-network-partners/